Ornithine transcarbamylase

Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Wednesday, July 28, 2021

The ARCT-810 Phase 2 study is a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose design for adolescents and adults with OTC deficiency.

Key Points: 
  • The ARCT-810 Phase 2 study is a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose design for adolescents and adults with OTC deficiency.
  • We are pleased to initiate this multiple dose Phase 2 clinical trial of ARCT-810 in OTC deficiency patients.
  • Advancement to a Phase 2 study is supported by the safety results from our ARCT-810 Phase 1 trial in Healthy Volunteers, said Steve Hughes, M.D., Chief Medical Officer of Arcturus.
  • Ornithine Transcarbamylase (OTC) deficiency is a serious urea cycle disorder with a prevalence of approximately 10,000 people worldwide.

PURA With ALKM and USMJ Schedules Strategic Transition Preview For Next Week

Retrieved on: 
Friday, May 28, 2021

The preview will include covering the rolls Alkame Holdings, Inc. (OTC Pink: ALKM) and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) play in the transition plan in addition to an update on PURA's business relationship with PAO Group, Inc. (OTC Pink: PAOG).

Key Points: 
  • The preview will include covering the rolls Alkame Holdings, Inc. (OTC Pink: ALKM) and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) play in the transition plan in addition to an update on PURA's business relationship with PAO Group, Inc. (OTC Pink: PAOG).
  • As part of a growing partnership, PURA has recently acquired a five percent stake in ALKM .
  • PURA management has remained convinced that the cannabis market remains rich with opportunity well beyond smokables, infused consumables, nutraceuticals and pharmaceuticals.
  • Learn more on Thursday next week when PURA releases the transition preview.

Medivolve Announces an Investor Webinar Tuesday, May 11 at 11 am ET

Retrieved on: 
Thursday, May 6, 2021

Participants will have the opportunity to ask questions during the Q&A session.\nMedivolve\xc2\xa0Inc.

Key Points: 
  • Participants will have the opportunity to ask questions during the Q&A session.\nMedivolve\xc2\xa0Inc.
  • (NEO:MEDV; OTC:COPRF; FRA:4NC) focuses on commercializing technologies to help transform human health management.
  • This includes providing convenient and accessible medical services for testing, prevention and treatment.
  • Accordingly, readers should not place undue reliance on forward-looking information.

Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Monday, December 7, 2020

The ongoing Phase 1b study will evaluate approximately twelve patients with OTC deficiency.

Key Points: 
  • The ongoing Phase 1b study will evaluate approximately twelve patients with OTC deficiency.
  • Arcturus previously announced that it had completed the ARCT-810 Phase 1, dose escalation study in healthy subjects, at doses up to 0.4 mg/kg.
  • We are pleased to have now initiated dosing of ARCT-810 in patients with OTC deficiency.
  • Ornithine Transcarbamylase (OTC) deficiency is a serious urea cycle disorder with a prevalence of approximately 10,000 worldwide.

OTC Braces & Supports Markets 2020-2025 and Impact of COVID-19

Retrieved on: 
Wednesday, August 12, 2020

The recent COVID-19 global pandemic has also impacted the OTC orthopedic braces and supports market.

Key Points: 
  • The recent COVID-19 global pandemic has also impacted the OTC orthopedic braces and supports market.
  • The knee braces and supports segment to witness the highest growth rate in the OTC orthopedic braces and supports market, by product, during the forecast period.
  • The preventive care segment accounted for the largest share of the OTC orthopedic braces and supports market, by application, in 2019.
  • The pharmacies & retailers segment accounted for the largest share of the OTC orthopedic braces and supports market, by distribution channel, in 2019
    The pharmacies & reatilers segment accounted for the largest share of the OTC orthopedic braces and supports industry in 2019.

BioStem Technologies, Inc. Announces Update Regarding Timeline to Become Current Reporting with OTC Markets During Q4 2020

Retrieved on: 
Wednesday, July 22, 2020

BioStem's Chief Executive Officer, Jason Matuszewski, commented, "We are committed to completing our financial statements to become current in our OTC Markets reporting as soon as possible.

Key Points: 
  • BioStem's Chief Executive Officer, Jason Matuszewski, commented, "We are committed to completing our financial statements to become current in our OTC Markets reporting as soon as possible.
  • We are highly focused on accomplishing all necessary steps to get BioStem OTC Market's Current while continuing to improve the lives of patients and their families.
  • About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine.
  • BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.

ViaDerma, Inc. Provides a Corporate Update

Retrieved on: 
Tuesday, June 23, 2020

Upon completion of those amendments anticipated in the coming days ViaDerma is expected to return to a current filing status on OTC Markets.

Key Points: 
  • Upon completion of those amendments anticipated in the coming days ViaDerma is expected to return to a current filing status on OTC Markets.
  • Dr. Christopher Otiko, President of ViaDerma, said I am very pleased with the progress we are making on several fronts.
  • Possible future synergies between the companies may be explored down the road, though there are no collaborations at this time.
  • Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements.

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Friday, June 5, 2020

We are excited to advance ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency, into a Phase 1 study.

Key Points: 
  • We are excited to advance ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency, into a Phase 1 study.
  • This important milestone marks Arcturus transition into a clinical stage biopharmaceutical company, said Steve Hughes, M.D., Chief Development Officer of Arcturus.
  • The ARCT-810 Phase 1 study is a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers.
  • Ornithine Transcarbamylase (OTC) deficiency is a serious, urea cycle disorder with a prevalence of approximately 10,000 worldwide.

Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

Retrieved on: 
Monday, April 13, 2020

ARCT-810, Arcturus first development candidate, represents a novel approach to treat ornithine transcarbamylase deficiency.ARCT-810 is based on Arcturus mRNA design construct and proprietary manufacturing process.

Key Points: 
  • ARCT-810, Arcturus first development candidate, represents a novel approach to treat ornithine transcarbamylase deficiency.ARCT-810 is based on Arcturus mRNA design construct and proprietary manufacturing process.
  • ARCT-810 also utilizes Arcturus extensive and propriety lipid library and employs the Company's LUNAR delivery platform to deliver OTC mRNA to hepatocytes.
  • ARCT-810 is an investigational mRNA medicine designed to enable OTC-deficient patients to naturally produce healthy functional OTC enzyme in their own liver cells.
  • Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle disorder.

OTC Braces & Supports Market Worth $1.5 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, July 23, 2019

Soft & elastic braces and supports segment to register the highest growth in the OTC Braces and Supports Market, by type, during the forecast period

Key Points: 
  • Soft & elastic braces and supports segment to register the highest growth in the OTC Braces and Supports Market, by type, during the forecast period
    The soft & elastic braces and supports segment is expected to grow at the highest CAGR during the forecast period.
  • Preventive care segment accounted for the largest share of the OTC Braces and Supports Market, by application, in 2018
    Preventive care is the largest application segment of the OTC Braces and Supports Market, and this trend is expected to continue during the forecast period.
  • The OTC Braces and Supports Market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
  • North America accounted for the largest share of the OTC Braces and Supports Market in 2018.